Thomas Michael, Spigel David R, Jotte Robert M, McCleod Michael, Socinski Mark A, Page Ray D, Gressot Laurent, Knoble Jeanna, Juan Oscar, Morgensztern Daniel, Isla Dolores, Kim Edward S, West Howard, Ko Amy, Ong Teng Jin, Trunova Nataliya, Gridelli Cesare
Department of Thoracic Oncology/Internal Medicine, Thoraxklinik im Universitätsklinikum Heidelberg.
Translational Lung Research Center Heidelberg, Heidelberg, Germany.
Lung Cancer (Auckl). 2017 Oct 30;8:207-216. doi: 10.2147/LCTT.S138570. eCollection 2017.
Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of -paclitaxel/carboplatin combination chemotherapy.
Patients received -paclitaxel 100 mg/m days 1, 8, 15 + carboplatin area under the curve 6 mg•min/mL day 1 (q3w) for four cycles. QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and Euro-QoL-5 Dimensions-5 Levels (EQ-5D-5L) at baseline and each cycle (day 1).
Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1 postbaseline QoL assessment and were QoL evaluable. LCSS average total score and symptom burden index improved from baseline throughout four cycles. In the LCSS pulmonary symptoms score, 46% of patients reported clinically meaningful improvement (≥10 mm visual analog scale) from baseline. Individual EQ-5D-5L dimensions remained stable/improved in ≥83% of patients; ≈33% reported complete resolution of baseline problems at least once during four cycles. Generally, responders (unconfirmed complete/partial response) had higher scores vs nonresponders.
In patients with squamous NSCLC, four cycles of -paclitaxel/carboplatin demonstrated clinically meaningful QoL improvements, with greater benefits in responders vs nonresponders.
关于治疗对晚期非小细胞肺癌（NSCLC）患者生活质量（QoL）影响的纵向数据有限。在这种姑息治疗环境中，不降低生活质量的治疗是关键。在此，我们报告接受≤4周期紫杉醇/卡铂联合化疗的鳞状NSCLC患者的纵向生活质量。
患者在第1、8、15天接受100mg/m²紫杉醇 + 第1天曲线下面积为6mg•min/mL的卡铂（每3周一次），共四个周期。在基线和每个周期（第1天）通过肺癌症状量表（LCSS）和欧洲五维健康量表-5级（EQ-5D-5L）评估生活质量。
206例可进行病灶反应评估的患者完成了基线 + ≥1次基线后生活质量评估且可进行生活质量评估。在四个周期中，LCSS平均总分和症状负担指数较基线均有所改善。在LCSS肺部症状评分中，46%的患者报告与基线相比有临床意义的改善（视觉模拟量表≥10mm）。≥83%的患者EQ-5D-5L各维度保持稳定/改善；约33%的患者报告在四个周期中至少有一次基线问题完全缓解。一般来说，有反应者（未确认的完全/部分缓解）的得分高于无反应者。
在鳞状NSCLC患者中，四个周期的紫杉醇/卡铂治疗显示出有临床意义的生活质量改善，有反应者比无反应者获益更大。
